I Kausch von SchmelingSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancerIngo Kausch
Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany
Expert Rev Anticancer Ther 6:1301-11. 2006..Additional approaches, such as photodynamic therapy with different photosensitizers and thermotherapy in combination with intravesical chemotherapy, have been evaluated in Phase III studies...
[Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art]I Kausch von Schmeling
Klinik für Urologie, Universitat zu Lubeck, UK S H, Lubeck
Aktuelle Urol 41:307-15. 2010..The question as to what has to be done in failure after BCG is discussed. Cystectomy is a safe option but other approaches are potential alternatives...
[Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis]I Kausch
Klinik für Urologie, Universitat zu Lubeck, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Lubeck, Deutschland
Aktuelle Urol 41:171-7. 2010..Heterogeneous results of single studies with photodynamic diagnosis (PDD) in bladder cancer have been reported. A metaanalysis of prospective studies has now been performed...
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studiesIngo Kausch
Department of Urology, University at Lubeck, University Hospital Schleswig Holstein, Campus Lubeck, Lubeck, Germany
Eur Urol 57:595-606. 2010..The clinical benefit of photodynamic diagnosis (PDD) with 5-aminolevulinic acid or hexaminolevulinate in addition to white-light cystoscopy (WLC) in bladder cancer has been discussed controversially...
[Endourological lithotripsy for stone removal: accidental fragmentation of dormia basket and guidewire - a brief overview]J Cordes
Klinik für Urologie, Campus Lubeck, Universitatsklinikum Schleswig Holstein, Ratzeburger Allee 160, 23538 Lubeck, Deutschland
Urologe A 49:1365-7. 2010..In this article we describe the energy needed for destroying specific foreign bodies and what currently and in the future will be the best way to avoid this problem...
[Squamous cell carcinoma of the renal pelvis. Therapeutic options for a rare entity]B Kazarians
Klinik und Poliklinik fur Urologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck
Aktuelle Urol 39:456-8. 2008..The patient with SCC described here showed an above-average survival of 18 months after adjuvant radiochemotherapy. Treatment was initiated according to the guidelines for squamous cell carcinoma in non-urological localisations...
In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancerCaroline E Blietz
Department of Urology, University of Lubeck, Lubeck, Germany
In Vivo 23:13-9. 2009..In search of new agents, antisense oligonucleotides (AS-ON) may be interesting candidates. The availability and toxicity as well as the effectivity of AS-ON after intravesical instillation in different rodent models were examined...
Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinomaStefan Kruger
Department of Pathology, University of Schleswig Holstein, Lubeck, Germany
Urology 67:105-9. 2006..To determine whether clusterin immunoreactivity of muscle-invasive bladder carcinoma can predict disease-related survival of patients treated by radical cystectomy...
Expression of KIT (CD117) in renal cell carcinoma and renal oncocytomaStefan Kruger
Institute of Pathology, University of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
Oncology 68:269-75. 2005..Our aim was to analyze KIT expression immunohistochemically in renal cell carcinomas (RCCs) and in oncocytomas...
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implicationsStefan Kruger
Institute of Pathology, University of Schleswig Holstein, Lubeck, Germany
Anticancer Res 25:263-71. 2005..Due to their variable clinical course, there is a need for new prognostic parameters in minimally invasive (stage T1) bladder carcinomas...
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancerMerle Hanke
Kompetenzzentrum fuer Drug Design und Target Monitoring, Luebeck, Germany
Clin Chem 53:2070-7. 2007..We aimed to develop a procedure for measurement of tumor RNA in urine that would minimize donor-dependent influences on the results...
